{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:30:27Z","timestamp":1761895827003,"version":"3.44.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T00:00:00Z","timestamp":1583193600000},"content-version":"vor","delay-in-days":1919,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.ad.2013.10.020","type":"journal-article","created":{"date-parts":[[2014,3,25]],"date-time":"2014-03-25T09:39:19Z","timestamp":1395740359000},"page":"913-922","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Actualizaci\u00f3n en artritis psori\u00e1sica"],"prefix":"10.1016","volume":"105","author":[{"given":"A.","family":"L\u00f3pez-Ferrer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Laiz-Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ad.2013.10.020_bib0005","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3899\/jrheum.120232","article-title":"Pathogenetic overview of psoriatic disease","volume":"89","author":"Haroon","year":"2012","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.ad.2013.10.020_bib0010","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s11926-012-0257-3","article-title":"Is psoriatic arthritis a result of abnormalities in acquired or innate immunity?","volume":"14","author":"Lories","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.ad.2013.10.020_bib0015","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev-pathol-011811-132448","article-title":"Psoriasis","volume":"7","author":"Perera","year":"2012","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.ad.2013.10.020_bib0020","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.ajhg.2012.03.012","article-title":"PSORS2 is due to mutations in CARD14","volume":"90","author":"Jordan","year":"2012","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.ad.2013.10.020_bib0025","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/ncprheum0987","article-title":"New insights into the pathogenesis and genetics of psoriatic arthritis","volume":"5","author":"Nograles","year":"2009","journal-title":"Nat Clin Pract Rheumatol"},{"key":"10.1016\/j.ad.2013.10.020_bib0030","doi-asserted-by":"crossref","first-page":"R326","DOI":"10.1186\/ar1182","article-title":"Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: A prospective single-centre study","volume":"6","author":"Goedkoop","year":"2004","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ad.2013.10.020_bib0035","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1002\/art.20181","article-title":"Antiangiogenic effects of anti-tumor necrosis factor alpha therapy with infliximab in psoriatic arthritis","volume":"50","author":"Ca\u00f1ete","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ad.2013.10.020_bib0040","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJMoa1109017","article-title":"Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis","volume":"366","author":"Papp","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2013.10.020_bib0045","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","article-title":"Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis","volume":"366","author":"Leonardi","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2013.10.020_bib0050","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/nrrheum.2011.169","article-title":"Genetics of susceptibility and treatment response in psoriatic arthritis","volume":"7","author":"O\u2019Rielly","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ad.2013.10.020_bib0055","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/ng.2467","article-title":"Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity","volume":"44","author":"Tsoi","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.ad.2013.10.020_bib0060","doi-asserted-by":"crossref","first-page":"e19454","DOI":"10.1371\/journal.pone.0019454","article-title":"A genetic risk score combining ten psoriasis risk loci improves disease prediction","volume":"6","author":"Chen","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ad.2013.10.020_bib0065","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1013068","article-title":"Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis","volume":"365","author":"Marrakchi","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ad.2013.10.020_bib0070","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1093\/hmg\/dds295","article-title":"Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes","volume":"21","author":"Julia","year":"2012","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ad.2013.10.020_bib0075","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1136\/ard.2011.150102","article-title":"Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis","volume":"70","author":"Bowes","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2013.10.020_bib0080","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1136\/ard.2010.147793","article-title":"The association between smoking and the development of psoriatic arthritis among psoriasis patients","volume":"71","author":"Eder","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2013.10.020_bib0085","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework","volume":"69","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ad.2013.10.020_bib0090","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1365-2133.2008.08628.x","article-title":"Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis","volume":"159","author":"Strober","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2013.10.020_bib0095","first-page":"120","article-title":"Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis","volume":"27","author":"Alenius","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ad.2013.10.020_bib0100","first-page":"1087","article-title":"Increased serum levels of cartilage oligomeric matrix protein in patients with psoriasis vulgaris: A marker for unknown peripheral joint involvement?","volume":"26","author":"Skoumal","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ad.2013.10.020_bib0105","doi-asserted-by":"crossref","first-page":"R164","DOI":"10.1186\/ar3123","article-title":"Circulating mediators of bone remodeling in psoriatic arthritis: Implications for disordered osteoclastogenesis and bone erosion","volume":"12","author":"Dalbeth","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ad.2013.10.020_bib0110","doi-asserted-by":"crossref","first-page":"65","DOI":"10.3899\/jrheum.120247","article-title":"Soluble biomarkers may differentiate psoriasis from psoriatic arthritis","volume":"89","author":"Chandran","year":"2012","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.ad.2013.10.020_bib0115","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/rheumatology\/keq105","article-title":"Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis","volume":"49","author":"Chandran","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ad.2013.10.020_bib0120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/ar67","article-title":"Mechanisms of bone loss in inflammatory arthritis: Diagnosis and therapeutic implications","volume":"2","author":"Goldring","year":"2000","journal-title":"Arthritis Res"},{"key":"10.1016\/j.ad.2013.10.020_bib0125","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1002\/1529-0131(200002)43:2<250::AID-ANR3>3.0.CO;2-P","article-title":"Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor","volume":"43","author":"Gravallese","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ad.2013.10.020_bib0130","first-page":"809","article-title":"Longitudinal study of clinical and radiological progression in psoriatic arthritis","volume":"17","author":"Gladman","year":"1990","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ad.2013.10.020_bib0135","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/ard.2005.045658","article-title":"The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): Results of radiographic analyses after 1 year","volume":"65","author":"Kavanaugh","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2013.10.020_bib0140","first-page":"712","article-title":"Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept","volume":"33","author":"Mease","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ad.2013.10.020_bib0145","first-page":"17","article-title":"Correlations between peripheral and axial radiological changes in patients with psoriatic polyarthritis","volume":"63","author":"Taccari","year":"1996","journal-title":"Rev Rhum Engl Ed"},{"key":"10.1016\/j.ad.2013.10.020_bib0150","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/ard.62.1.68","article-title":"A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis","volume":"62","author":"Queiro-Silva","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2013.10.020_bib0155","first-page":"675","article-title":"Clinical indicators of progression in psoriatic arthritis: Multivariate relative risk model","volume":"22","author":"Gladman","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ad.2013.10.020_bib0160","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1136\/annrheumdis-2012-201580","article-title":"Bone anabolic changes progress in psoriatic arthritis patients despite treatment with methotrexate or tumour necrosis factor inhibitors","volume":"72","author":"Finzel","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2013.10.020_bib0165","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/art.33415","article-title":"HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype","volume":"64","author":"Winchester","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ad.2013.10.020_bib0170","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1136\/annrheumdis-2012-201706","article-title":"High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires","volume":"72","author":"Haroon","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2013.10.020_bib0175","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/rheumatology\/kes187","article-title":"The early psoriatic arthritis screening questionnaire: A simple and fast method for the identification of arthritis in patients with psoriasis","volume":"51","author":"Tinazzi","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ad.2013.10.020_bib0180","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/bjd.12190","article-title":"Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study)","volume":"168","author":"Coates","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2013.10.020_bib0185","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jaad.2005.03.046","article-title":"Epidemiology of psoriatic arthritis in the population of the United States","volume":"53","author":"Gelfand","year":"2005","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ad.2013.10.020_bib0190","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/art.24172","article-title":"Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: A population-based study","volume":"61","author":"Wilson","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ad.2013.10.020_bib0195","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1136\/ard.2011.150938","article-title":"Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?","volume":"70","author":"Gladman","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2013.10.020_bib0200","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: Development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ad.2013.10.020_bib0205","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1002\/art.34536","article-title":"Sensitivity and specificity of the classification of psoriatic arthritis criteria in early psoriatic arthritis","volume":"64","author":"Coates","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ad.2013.10.020_bib0210","first-page":"3","article-title":"The challenge of early diagnosis of psoriatic arthritis","volume":"35","author":"Olivieri","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ad.2013.10.020_bib0215","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/art.23104","article-title":"Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis","volume":"57","author":"Chandran","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ad.2013.10.020_bib0220","first-page":"1106","article-title":"Isolated peripheral enthesitis and\/or dactylitis: A subset of psoriatic arthritis","volume":"24","author":"Salvarani","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ad.2013.10.020_bib0225","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1365-2230.2007.02581.x","article-title":"Detection of subclinical joint involvement in psoriasis with bone scintigraphy and its response to oral methotrexate","volume":"33","author":"Raza","year":"2008","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2013.10.020_bib0230","first-page":"137","article-title":"Early psoriatic arthritis: The clinical spectrum","volume":"35","author":"Scarpa","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ad.2013.10.020_bib0235","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/000155598442809","article-title":"Subclinical joint involvement in psoriasis: Magnetic resonance imaging and X-ray findings","volume":"78","author":"Offidani","year":"1998","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ad.2013.10.020_bib0240","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ejrad.2007.08.005","article-title":"MR imaging features of foot involvement in patients with psoriasis","volume":"67","author":"Erdem","year":"2008","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.ad.2013.10.020_bib0245","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/ard.2007.075101","article-title":"Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: A hospital-based case-control study","volume":"67","author":"Gisondi","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2013.10.020_bib0250","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1517\/14656560802653198","article-title":"Treatment strategies for early psoriatic arthritis","volume":"10","author":"Olivieri","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ad.2013.10.020_bib0255","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/ard.2008.094946","article-title":"Treatment recommendations for psoriatic arthritis","volume":"68","author":"Ritchlin","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2013.10.020_bib0260","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.3899\/jrheum.090988","article-title":"Socioeconomic burden of psoriatic arthritis in Hong Kong: Direct and indirect costs and the influence of disease pattern","volume":"37","author":"Zhu","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ad.2013.10.020_bib0265","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/rheumatology\/ken320","article-title":"The psoriatic arthritis cost evaluation study: A cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy","volume":"47","author":"Olivieri","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ad.2013.10.020_bib0270","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s10067-011-1680-y","article-title":"The effectiveness and safety of TNF-alpha blockers in the treatment of early psoriatic arthritis: An Italian multicentre longitudinal observational pilot study","volume":"30","author":"Scarpa","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ad.2013.10.020_bib0275","first-page":"1842","article-title":"Comparison of disability and quality of life in rheumatoid and psoriatic arthritis","volume":"28","author":"Sokoll","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ad.2013.10.020_bib0280","first-page":"123","article-title":"The modified Nail Psoriasis Severity Index: Validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis","volume":"34","author":"Cassell","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ad.2013.10.020_bib0285","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"Infliximab improves signs and symptoms of psoriatic arthritis: Results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2013.10.020_bib0290","first-page":"1302","article-title":"Measuring dactylitis in clinical trials: Which is the best instrument to use?","volume":"34","author":"Healy","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ad.2013.10.020_bib0295","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/art.23568","article-title":"Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis","volume":"59","author":"Healy","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ad.2013.10.020_bib0300","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.3899\/jrheum.080491","article-title":"Psoriatic arthritis spondylitis radiology index: a modified index for radiologic assessment of axial involvement in psoriatic arthritis","volume":"36","author":"Lubrano","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ad.2013.10.020_bib0305","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/art.1780380602","article-title":"American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis","volume":"38","author":"Felson","year":"1995","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ad.2013.10.020_bib0310","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1002\/art.1780391210","article-title":"Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study","volume":"39","author":"Clegg","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ad.2013.10.020_bib0315","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: A proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2013.10.020_bib0320","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/ard.49.11.916","article-title":"Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score","volume":"49","author":"Van der Heijde","year":"1990","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2013.10.020_bib0325","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1136\/ard.2006.051706","article-title":"Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: Analysis of data from randomised controlled trials of two tumour necrosis factor inhibitors","volume":"65","author":"Fransen","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2013.10.020_bib0330","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/art.22531","article-title":"The Disease Activity Score in 28 joints in rheumatoid arthritis and psoriatic arthritis patients","volume":"57","author":"Leeb","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ad.2013.10.020_bib0335","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/annrheumdis-2012-201341","article-title":"The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)","volume":"72","author":"Helliwell","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2013.10.020_bib0340","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/annrheumdis-2011-200350","article-title":"European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies","volume":"71","author":"Gossec","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2013.10.020_bib0345","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","article-title":"Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double-blind, randomized, placebo-controlled clinical trial","volume":"50","author":"Kaltwasser","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ad.2013.10.020_bib0350","first-page":"589","article-title":"Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: A one-year prospective study","volume":"13","author":"Spadaro","year":"1995","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ad.2013.10.020_bib0355","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.1780270403","article-title":"Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis","volume":"27","author":"Willkens","year":"1984","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ad.2013.10.020_bib0360","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2013.10.020_bib0365","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: Safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ad.2013.10.020_bib0375","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1136\/annrheumdis-2012-202229","article-title":"Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: A population-based regional Swedish cohort study","volume":"72","author":"Kristensen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2013.10.020_bib0380","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1365-2133.2012.11015.x","article-title":"A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis","volume":"167","author":"Gottlieb","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2013.10.020_bib0385","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/ard.2008.092767","article-title":"Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)","volume":"68","author":"Mease","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2013.10.020_bib0390","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1136\/ard.2011.152223","article-title":"Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: The RESPOND study","volume":"71","author":"Baranauskaite","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2013.10.020_bib0395","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2230.2008.02946.x","article-title":"Long-term control of recalcitrant psoriasis with combination infliximab and methotrexate","volume":"34","author":"Warren","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.ad.2013.10.020_bib0400","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/ard.2010.129916","article-title":"Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis","volume":"70","author":"Greenberg","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2013.10.020_bib0405","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1001\/archdermatol.2012.2502","article-title":"Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis","volume":"148","author":"Wu","year":"2012","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ad.2013.10.020_bib0410","doi-asserted-by":"crossref","first-page":"179","DOI":"10.3109\/09546634.2012.672710","article-title":"Investigator-initiated, open-label trial of ustekinumab for the treatment of moderate-to-severe palmoplantar psoriasis","volume":"24","author":"Au","year":"2013","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.ad.2013.10.020_bib0415","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","article-title":"Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial","volume":"373","author":"Gottlieb","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2013.10.020_bib0420","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2013.10.020_bib0425","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study","volume":"167","author":"Papp","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ad.2013.10.020_bib0430","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1185\/030079908X301866","article-title":"An open-label, single-arm pilot study in patients with severe plaque-type psoriasis treated with an oral anti-inflammatory agent, apremilast","volume":"24","author":"Gottlieb","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ad.2013.10.020_bib0435","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0140-6736(12)60642-4","article-title":"Efficacy of apremilast in the treatment of moderate to severe psoriasis: A randomised controlled trial","volume":"380","author":"Papp","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ad.2013.10.020_bib0440","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1002\/art.34627","article-title":"Oral apremilast in the treatment of active psoriatic arthritis: Results of a multicenter, randomized, double-blind, placebo-controlled study","volume":"64","author":"Schett","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ad.2013.10.020_bib0445","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1136\/annrheumdis-2012-201601","article-title":"Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: A 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial","volume":"72","author":"McInnes","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2013.10.020_bib0450","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/art.22884","article-title":"High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors","volume":"57","author":"Gonzalez-Juanatey","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ad.2013.10.020_bib0455","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/art.22530","article-title":"Endothelial dysfunction in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors","volume":"57","author":"Gonzalez-Juanatey","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ad.2013.10.020_bib0460","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1136\/ard.2008.094839","article-title":"Cardiovascular morbidity in psoriatic arthritis","volume":"68","author":"Gladman","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ad.2013.10.020_bib0465","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"Reiner","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ad.2013.10.020_bib0470","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/j.1365-2133.2008.09023.x","article-title":"Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis","volume":"160","author":"Reich","year":"2009","journal-title":"Br J Dermatol"}],"container-title":["Actas Dermo-Sifiliogr\u00e1ficas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731014000702?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001731014000702?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T01:02:54Z","timestamp":1757552574000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001731014000702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":93,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0001731014000702"],"URL":"https:\/\/doi.org\/10.1016\/j.ad.2013.10.020","relation":{},"ISSN":["0001-7310"],"issn-type":[{"type":"print","value":"0001-7310"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Actualizaci\u00f3n en artritis psori\u00e1sica","name":"articletitle","label":"Article Title"},{"value":"Actas Dermo-Sifiliogr\u00e1ficas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ad.2013.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Espa\u00f1a, S.L.U. y AEDV. All rights reserved.","name":"copyright","label":"Copyright"}]}}